Chiesi Farmaceutici S.p.a.
Clinical trials sponsored by Chiesi Farmaceutici S.p.a., explained in plain language.
-
New Eco-Friendly asthma inhaler tested for safety
Disease control CompletedThis study tested whether an asthma medication using a new, more environmentally friendly propellant (HFA-152a) is as safe as the current version (HFA-134a). Researchers enrolled 836 adults with moderate to severe asthma to compare breathing effects and safety over 12 weeks. The …
Phase: PHASE3 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
Major trial tests Triple-Drug inhaler for better COPD control
Disease control CompletedThis large, year-long study compared a new triple-drug inhaler to a standard dual-drug inhaler for people with chronic obstructive pulmonary disease (COPD). Over 3,400 participants used one of the inhalers daily to see which was better at improving breathing and reducing serious …
Phase: PHASE3 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
New asthma inhaler combo tested for better breathing
Disease control CompletedThis study tested if a new combination inhaler (CHF 1535) works better than a standard steroid inhaler (CHF 718) for adults with moderate-to-severe asthma. Over 1,300 participants used one of the two inhalers for 12 weeks. Researchers measured lung function, asthma symptoms, and …
Phase: PHASE3 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New inhaler tested to help adults breathe easier
Disease control CompletedThis study tested if a new combination inhaler (CHF 1535) was better than a standard steroid inhaler at improving lung function in adults whose asthma was not well-controlled on their current medication. Over 500 participants used one of the two inhalers for 12 weeks while resear…
Phase: PHASE3 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New Triple-Threat inhaler put to the test in major COPD study
Disease control CompletedThis study looked at how well a three-in-one inhaler works for people with COPD in their everyday lives. It followed 362 adults in China for 12 weeks to see if the inhaler improved their breathing symptoms and lung function. The goal was to gather real-world evidence on controlli…
Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
Doctors track bleeding risks in 1,000+ heart attack patients
Knowledge-focused CompletedThis study observed over 1,000 heart attack patients who received a specific intravenous blood thinner (cangrelor) during a procedure to open blocked heart arteries. Researchers tracked patients for 30 days as they switched from the IV medication to common oral blood thinners. Th…
Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Knowledge-focused
Last updated Apr 03, 2026 14:43 UTC
-
Scientists test how Teens' bodies handle asthma drug
Knowledge-focused CompletedThis study aimed to understand how a potential new asthma drug is processed by the body. Researchers compared the drug levels in the blood of 25 teenagers and 25 adults with stable asthma after they inhaled a single dose. The main goal was to see if the drug behaves similarly in …
Phase: PHASE2 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:31 UTC
-
Scientists test drug mix for future lung disease treatment
Knowledge-focused CompletedThis early-stage study aimed to understand how a drug called cyclosporine, often used after organ transplants, might affect the body's processing of an experimental medication for COPD (CHF6001). Thirty healthy volunteers took the COPD drug alone and then again after taking cyclo…
Phase: PHASE1 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:15 UTC
-
First human tests for new lung scarring treatment
Knowledge-focused CompletedThis early-stage study tested the safety and how the body processes an inhaled drug called CHF10073, which is being developed for pulmonary fibrosis (lung scarring). It involved 155 healthy volunteers to check for side effects and measure drug levels in the blood and lungs. The m…
Phase: PHASE1 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Knowledge-focused
Last updated Mar 16, 2026 15:26 UTC